sponsored
PatientsVille.com Logo

PatientsVille

Palmoplantar Medical Research Studies

Up-to-date List of Palmoplantar Medical Research Studies

What Research is Being Done?

A clinical study involves research using human volunteers (also called participants) that is intended to add to medical knowledge. There are two main types of clinical studies: clinical trials (also called interventional studies) and observational studies. Following list includes both interventional and observational studies.

Latest Palmoplantar Medical Research Studies

Rank Status Study
1 Recruiting Apremilast in Palmo-Plantar Psoriasis
Condition: Palmo-plantar Psoriasis
Interventions: Drug: Apremilast;   Drug: Placebo
Outcome Measures: PPPGA of 0 or 1;   PPPGA;   PPPASI;   PPPSA;   Hand and Foot main measurement (VAS scale)
2 Unknown  Dandelion Juice in the Treatment of Dyshidrotic Hand Eczema
Conditions: Vesicular Palmoplantar Eczema;   Pompholyx
Intervention: Drug: dandelion juice
Outcome Measures: Improvement in dyshidrotic hand eczema in the study period assessed by HECSI score.;   Improvement in dyshidrotic eczema in the study period assessed by the patient (Visual Analog Scale).
3 Recruiting MARY D&Apos;UOL REPAIR BALM IN THE PREVENTION OF SKIN TOXICITY BY CAPECITABINE
Condition: Dermatitis, Adverse Drug Reaction
Interventions: Procedure: BALM ARM;   Procedure: PLACEBO ARM
Outcome Measures: Percentage of patients who develop dermatologic toxicity.;   Need of pharmacological treatment to mitigate toxicity;   Quality of life
4 Unknown  Treatment of the Recessive Nonbullous Congenital Ichthyosis by the Epigallocatechine Cutaneous
Condition: Lamellar Ichthyosis
Intervention: Drug: apply VEREGEN ® 10 % on a randomized area and the moisturizing cream of the other side
Outcome Measures: action and the tolerance of a daily application of topical Polyphénon E 10% ®;   severity of the palmar and plantar involvement;   level of pruritus;   global tolerance and acceptability by the patient of the Polyphénon E ® ointment;   Relapse
5 Recruiting A Study Comparing Different Dosing Regimens of Ixekizumab (LY2439821) in Participants With Moderate to Severe Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Ixekizumab;   Drug: Placebo
Outcome Measures: Proportion of Participants Achieving Static Physician Global Assessment (sPGA) of (0,1);   Proportion of Participants Achieving 75% Improvement in Psoriasis Area and Severity Index (PASI 75);   Proportion of Participants Achieving sPGA (0);   Proportion of Participants Achieving PASI 90 and PASI 100;   Mean Change and Mean Percent Improvement of PASI from Baseline;   Mean Change from Baseline in Percent Body Surface Area (BSA) Involvement;   Mean Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Score;   Mean Change from Baseline in Psoriasis Scalp Severity Index (PSSI) Score;   Mean Change from Baseline in Palmoplantar PASI (PPASI);   Proportion of Participants Achieving an Itch Numeric Rating Scale (Itch NRS) ≥4 point Reduction from Baseline;   Proportion of Participants Achieving Dermatology Life Quality Index (DLQI) total score of 0 and 1 (DLQI [0,1]);   Mean Change from Baseline in DLQI Total Score and Domains, Itch NRS score, and Skin Pain Visual Analog Scale (VAS);   Mean Change from Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D-5L) VAS;   Pharmacokinetics (PK): Trough Concentration at Steady State (Ctrough,ss) of Ixekizumab;   Number of Participants with Anti-Ixekizumab Antibodies
6 Not yet recruiting A Study of Ixekizumab (LY2439821) in Participants With Moderate-to-Severe Plaque Psoriasis
Condition: Plaque Psoriasis
Interventions: Drug: Ixekizumab;   Drug: Ustekinumab
Outcome Measures: Proportion of Participants with a ≥90% Improvement in Psoriasis Area and Severity Index (PASI 90) from Baseline;   Proportion of Participants with a ≥75% Improvement in PASI (PASI 75) from Baseline;   Proportion of Participants with a 100% Improvement of PASI (PASI 100) from Baseline;   Proportion of Participants with a Static Physician Global Assessment (sPGA) (0,1) with at Least a 2-Point Improvement from Baseline;   Proportion of Participants with a sPGA (0) Remission;   Change from Baseline in Body Surface Area (BSA) Affected by Psoriasis;   Change from Baseline in Palmoplantar Psoriasis Severity Index (PPASI) Total Score;   Change from Baseline in Psoriasis Scalp Severity Index (PSSI) Total Score;   Change from Baseline in Nail Psoriasis Severity Index (NAPSI) Total Score;   Change from Baseline in Itch Numeric Rating Scale (NRS);   Change from Baseline on the Skin Pain Visual Analog Scale (VAS) (0,100);   Proportion of Participants with Dermatology Life Quality Index (DLQI) (0,1);   Change from Baseline on the Hospital Anxiety and Depression Scale (HADS) Depression and HADS Anxiety Subscales;   Change from Baseline in Medical Outcomes Study 36-Item Short Form Health Survey (SF-36) Physical Component Summary (PCS) and Mental Component Summary (MCS) Scores;   Change from Baseline on Patient Global Assessment of Disease Severity;   Change from Baseline in European Quality of Life - 5 Dimensions 5 Level (EQ-5D 5L) "Bolt On" Index, EQ-5D Utility Index and VAS;   Change From Baseline on the Work Productivity Activity Impairment Questionnaire-Psoriasis (WPAI-PSO)

These studies may lead to new treatments and are adding insight into Palmoplantar etiology and treatment.

A major focus of Palmoplantar research is the development of new drugs and other treatment options. Studies seek to identify new drugs to treat various related disorders and to find safer, more effective doses for medications already being used. Other research is aimed at identifying receptors or drug targets.


Discuss Palmoplantar